Donepezil Double Blind Trial for ECT Memory Disfunction

• Status: Unknown status
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.

Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BeerYaakov Mental Health Center
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)

Exclusion Criteria:

• History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.

• Pregnant women

• Patients who recieved ECT within 6 month

• Patients whith contraindication to Donepezil treatment.

• Patients with Lithium treatment